CareTalk: Healthcare. Unfiltered. What JPM Signals for Healthcare in 2026
8 snips
Jan 23, 2026 The discussion centers on the implications of the JPMorgan Health Care Conference for the future of healthcare. GLP-1s are highlighted as a powerful force, with their metabolic benefits drawing intense interest from pharma. AI's transformative role is explored, particularly how it's driving advancements in healthcare technology. The impact of China's rising biotech capabilities raises concerns about competitiveness and security. The conversation emphasizes the evolving landscape and what it could mean for healthcare by 2026.
AI Snips
Chapters
Transcript
Episode notes
GLP-1s Are A Broad, Growing Wave
- GLP-1 drugs are creating a major wave across pharma, services, plans, and consumers due to strong weight-loss and metabolic effects.
- Orals and broader indications may increase adherence and expand clinical impact beyond obesity.
Companion Services Will Multiply Around GLP-1s
- Companion services (strength training, nutrition, adherence programs) will arise to capture full clinical benefit of GLP-1s.
- These services address muscle loss and sustain health gains after weight loss.
AI's Short-Term Win Is Administrative Work
- Big tech, hyperscalers, and chipmakers converged at JPM to pursue healthcare use cases for AI and LLMs.
- The most immediate gains will likely be in administrative cost reduction rather than clinical breakthroughs.